Structure Therapeutics Inc.

Report azionario NasdaqGM:GPCR

Capitalizzazione di mercato: US$2.9b

Structure Therapeutics Gestione

Criteri Gestione verificati 3/4

Structure Therapeutics Il CEO è Raymond Stevens, nominato in May2019, e ha un mandato di 7.25 anni. la retribuzione annua totale è $ 8.43M, composta da 8% di stipendio e 92% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.15% delle azioni della società, per un valore di $ 62.49M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 3.4 anni.

Informazioni chiave

Raymond Stevens

Amministratore delegato

US$8.4m

Compenso totale

Percentuale dello stipendio del CEO7.97%
Mandato del CEO7yrs
Proprietà del CEO2.2%
Durata media del management3.9yrs
Durata media del Consiglio di amministrazione3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Apr 08

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

Summary Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario. Phase 3 Aleniglipron trial is the key catalyst, with a modeled 67.7% probability of success and potential $6B peak global sales. Read the full article on Seeking Alpha
Articolo di analisi • Jun 24

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 20

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Summary Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. With experienced management and multiple upcoming catalysts, Structure could see significant value growth or a potential Big Pharma acquisition. Read the full article on Seeking Alpha
Articolo di analisi • Mar 11

We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Structure Therapeutics: Competitive Data Is Emerging

Summary Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron demonstrated superior weight loss, but GSBR-1290's late improvements indicate it might catch up with extended treatment. Financially, Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully realized yet. The weight loss market is projected to reach $200bn by 2029, offering significant prospects for GSBR-1290 despite competitive and developmental risks. Read the full article on Seeking Alpha
Articolo di analisi • Nov 25

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 22

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Summary Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024. LTSE-2578 is being developed in phase 1 study targeting patients with idiopathic pulmonary fibrosis; the global idiopathic pulmonary fibrosis market is expected to reach $11.7 billion by 2031. Read the full article on Seeking Alpha
Articolo di analisi • Aug 11

We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 14

Structure Therapeutics: Yet Another Potential GLP-1 Entrant

Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatment landscape. The company used the spike in the stock to raise additional capital this month. Can Structure compete against Eli Lilly, Novo Nordisk and a host of other potential entrants in an increasingly crowded GLP-1 space? We look at the GLP-1 competitive landscape as well as Structure's prospects in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jun 05

Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape

Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is stable with over three years of cash runway. Hold recommendation for GPCR stock; GSBR-1290 has potential, but competition and adverse effects warrant caution. Read the full article on Seeking Alpha
Articolo di analisi • Mar 10

Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jun 29

Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Raymond Stevens rispetto agli utili di Structure Therapeutics?
DataCompenso totaleStipendioUtili della società
Dec 31 2025US$8mUS$672k

-US$141m

Sep 30 2025n/an/a

-US$211m

Jun 30 2025n/an/a

-US$179m

Mar 31 2025n/an/a

-US$143m

Dec 31 2024US$6mUS$634k

-US$123m

Sep 30 2024n/an/a

-US$111m

Jun 30 2024n/an/a

-US$100m

Mar 31 2024n/an/a

-US$98m

Dec 31 2023US$7mUS$596k

-US$90m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$747kUS$487k

-US$53m

Sep 30 2022n/an/a

-US$56m

Dec 31 2021US$1mUS$420k

-US$44m

Compensazione vs Mercato: La retribuzione totale di Raymond ($USD 8.43M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 7.13M ).

Compensazione vs guadagni: La retribuzione di Raymond è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Raymond Stevens (61 yo)

7yrs
Mandato
US$8,429,887
Compensazione

Dr. Raymond C. Stevens, Ph.D. is Professor of Molecular Biology and Chemistry at The Scripps Research Institute, La Jolla, California since 1999 until July 2014. He has been the Chief Executive Officer at...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Raymond Stevens
CEO & Director7yrsUS$8.43m2.15%
$ 62.5m
Jun Yoon
Co- Founder4yrsUS$4.47m1.26%
$ 36.5m
Yingli Ma
Chief Technology Officer3.8yrsUS$2.00m0.014%
$ 394.2k
Xichen Lin
Chief Scientific Officer & GM of Structure Shanghai6.8yrsUS$2.48m0.032%
$ 933.5k
Blai Coll
Chief Medical Officer1.7yrsUS$3.25m0.022%
$ 643.2k
Matthew Lang
COO & General Counselless than a yearNessun datoNessun dato
Bob Gatmaitan
Senior Vice President of People2.5yrsNessun datoNessun dato
Hui Lei
Senior Vice President of Chemistry4.3yrsNessun datoNessun dato
Fang Zhang
Executive VP & Head of Biologyno dataNessun datoNessun dato
Lani Ibarra
Senior Vice President of Clinical Development Operationsno dataNessun datoNessun dato
Tony Peng
Senior Vice President of Legalno dataNessun datoNessun dato
Xinglong Jiang
Senior Vice President of Preclinical Developmentno dataNessun datoNessun dato
3.9yrs
Durata media
51yo
Età media

Gestione esperta: Il team dirigenziale di GPCR è considerato esperto (durata media dell'incarico 3.9 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Raymond Stevens
CEO & Director7.3yrsUS$8.43m2.15%
$ 62.5m
Sharon Tetlow
Independent Director4.2yrsUS$360.03k0%
$ 0
Angus Russell
Independent Director1.8yrsUS$294.81k0%
$ 0
Daniel Welch
Independent Chairman4.3yrsUS$531.53k0.058%
$ 1.7m
Ted Love
Independent Director2.8yrsUS$357.53k0%
$ 0
Eric Dobmeier
Independent Director3.4yrsUS$352.53k0%
$ 0
Joanne Waldstreicher
Independent Director3.4yrsUS$355.03k0%
$ 0
3.4yrs
Durata media
65yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GPCR sono considerati esperti (durata media dell'incarico 3.4 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/07 18:01
Prezzo dell'azione a fine giornata2026/05/07 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Structure Therapeutics Inc. è coperta da 22 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Evan SeigermanBMO Capital Markets Equity Research
Edward NashCanaccord Genuity
Prakhar AgrawalCantor Fitzgerald & Co.